OMP and hepatocellular carcinoma: Early investigations include clinical trials NCT01351103, which examined LGK974 as a Wnt pathway inhibitor in malignancies dependent on this pathway, including HCC, and NCT02069145, which studied OMP-54F28 in combination with sorafenib in patients with HCC.